First-in-Class Selenium-Containing Potent Serotonin Receptor 5-HT 6 Agents with a Beneficial Neuroprotective Profile against Alzheimer’s Disease
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.3c02148 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Patryk Pyka und 35 weiteren Autor:innen. Beteiligte Einrichtung: Department of Technology and Biotechnology of Drugs, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland. Hauptthemen laut MEDLINE: Alzheimer Disease, Selenium, Neuroprotective Agents. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 131 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wydzial Lekarski, Uniwersytet Jagiellonski Collegium Medicum, Sapienza Universit? di Roma, European Regional Development Fund.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease (AD) has a complex and not-fully-understood etiology. Recently, the serotonin receptor 5-HT6 emerged as a promising target for AD treatment; thus, here a new series of 5-HT6R ligands with a 1,3,5-triazine core and selenoether linkers was explored. Among them, the 2-naphthyl derivatives exhibited strong 5-HT6R affinity and selectivity over 5-HT1AR (13-15), 5-HT7R (14 and 15), and 5-HT2AR (13). Compound 15 displayed high selectivity for 5-HT6R over other central nervous system receptors and exhibited low risk of cardio-, hepato-, and nephrotoxicity and no mutagenicity, indicating its "drug-like" potential. Compound 15 also demonstrated neuroprotection against rotenone-induced neurotoxicity as well as antioxidant and glutathione peroxidase (GPx)-like activity and regulated antioxidant and pro-inflammatory genes and NRF2 nuclear translocation. In rats, 15 showed satisfying pharmacokinetics, penetrated the blood-brain barrier, reversed MK-801-induced memory impairment, and exhibited anxiolytic-like properties. 15's neuroprotective and procognitive-like effects, stronger than those of the approved drug donepezil, may pave the way for the use of selenotriazines to inhibit both causes and symptoms in AD therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Technology and Biotechnology of Drugs, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland.
- Division of Bioorganic Chemistry, School of Pharmacy, Saarland University, Campus B 2.1, D-66123 Saarbrücken, Germany.
- Doctoral School of Medical and Health Sciences, Jagiellonian University Medical College, św. Łazarza 15, 31-530 Kraków, Poland.
- Department of Clinical Pharmacy, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland.
- Department of Medicinal Chemistry, Maj Institute of Pharmacology, Polish Academy of Sciences, Smętna 12, 31-343 Kraków, Poland.
- Department of Physiology and Pharmacology "V. Erspamer", Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy.
ORCID-Profile: Ewa Szymanska, Magdalena Jastrzębska-Więsek, Grzegorz Satała, Sabina Podlewska, Chiara Lambona, Francesco Marocco, Muhammad Jawad Nasim, Clemens Zwergel
Förderung
- Wydzial Lekarski, Uniwersytet Jagiellonski Collegium Medicum
- Sapienza Universit? di Roma
- European Regional Development Fund
- Narodowe Centrum Nauki
- Ministero dell'Universit? e della Ricerca
- KOHR GmbH
Zitieren
APA
Pyka, P., Haberek, W., Więcek, M., Szymanska, E., Ali, W., Cios, A., Jastrzębska-Więsek, M., Satała, G., Podlewska, S., Di Giacomo, S., Di Sotto, A., Garbo, S., Karcz, T., Lambona, C., Marocco, F., Latacz, G., Sudoł-Tałaj, S., Mordyl, B., Głuch-Lutwin, M., …, & Handzlik, J. (2024). First-in-Class Selenium-Containing Potent Serotonin Receptor 5-HT 6 Agents with a Beneficial Neuroprotective Profile against Alzheimer’s Disease. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c02148
Vancouver
Pyka P, Haberek W, Więcek M, Szymanska E, Ali W, Cios A, et al. First-in-Class Selenium-Containing Potent Serotonin Receptor 5-HT 6 Agents with a Beneficial Neuroprotective Profile against Alzheimer’s Disease. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.3c02148
BibTeX
@article{Pyka2024,
author = {Pyka, Patryk and Haberek, Wawrzyniec and Więcek, Małgorzata and Szymanska, Ewa and Ali, Wesam and Cios, Agnieszka and Jastrzębska-Więsek, Magdalena and Satała, Grzegorz and Podlewska, Sabina and Di Giacomo, Silvia and Di Sotto, Antonella and Garbo, Sabrina and Karcz, Tadeusz and Lambona, Chiara and Marocco, Francesco and Latacz, Gniewomir and Sudoł-Tałaj, Sylwia and Mordyl, Barbara and Głuch-Lutwin, Monika and Siwek, Agata and Czarnota-Łydka, Kinga and Gogola, Dawid and Olejarz-Maciej, Agnieszka and Wilczyńska-Zawal, Natalia and Honkisz-Orzechowska, Ewelina and Starek, Małgorzata and Dąbrowska, Monika and Kucwaj-Brysz, Katarzyna and Fioravanti, Rossella and Nasim, Muhammad Jawad and Hittinger, Marius and Partyka, Anna and Wesołowska, Anna and Battistelli, Cecilia and Zwergel, Clemens and Handzlik, Jadwiga},
title = {First-in-Class Selenium-Containing Potent Serotonin Receptor 5-HT 6 Agents with a Beneficial Neuroprotective Profile against Alzheimer’s Disease},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.3c02148}
}
EUVIMED